FP7H2020HORIZON
Great Ormond Street Hospital for Children Nhs Foundation Trust
- Country
- GBUnited Kingdom
- Defence projects
- 0
- Projects, all programmes
- 15
- As coordinator
- 0
- EU contribution (CORDIS)
- EUR 2,854,304
- Active
- 2008 to 2024
Projects
15 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| LightCureLightCure - Light for double specificity and efficacy without burden | HORIZON | 2024 | Associated partner | EUR 0 |
| Maxima ButterflyFrom Caterpillar to BUTTERFLY: supporting transformation of DCs in a paediatric oncology network | HORIZON | 2023 | Associated partner | EUR 0 |
| PHEMSPediatric Hospitals as European drivers for multi-party computation and synthetic data generation capabilities across clinical specialties and data types | HORIZON | 2023 | Associated partner | EUR 0 |
| BINDBrain Involvement iN Dystrophinopathies | H2020 | 2020 | Participant | EUR 41,097 |
| RECOMBStem-cell based gene therapy for recombination deficient SCID (RECOMB) | H2020 | 2018 | Participant | EUR 62,500 |
| SCIDNETDevelopIng Genetic medicines for Severe Combined Immunodeficiency (SCID) | H2020 | 2016 | Participant | EUR 423,198 |
| BOOSTB4Boost Brittle Bones Before Birth | H2020 | 2016 | Participant | EUR 1,088,078 |
| BETACUREPersonalized diagnosis and treatment of hyperinsulinemic hypoglycaemia caused by beta-cell pathology | FP7 | 2014 | Participant | EUR 47,929 |
| LENALabeling of Enalapril from Neonates up to Adolescents | FP7 | 2013 | Participant | EUR 266,484 |
| ESPOIREuropean clinical study for the application of regenerative heart valves | FP7 | 2012 | Participant | EUR 354,527 |
| SKIP-NMDA phase I/IIa clinical trial in Duchenne muscular dystrophy using systemically delivered morpholino antisense oligomer to skip exon 53 | FP7 | 2012 | Participant | EUR 295,388 |
| PANCARESURFUPPanCare Childhood and Adolescent Cancer Survivor Care and Follow-up Studies | FP7 | 2011 | Participant | EUR 85,000 |
| STOPSuicidality: Treatment Occurring in Paediatrics | FP7 | 2010 | Participant | Not stated |
| NEMOTreatment of NEonatal seizures with Medication Off-patent: evaluation of efficacy and safety of bumetanide | FP7 | 2009 | Participant | EUR 140,104 |
| EUNEFRONEuropean Network for the Study of Orphan Nephropathies | FP7 | 2008 | Participant | EUR 50,000 |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.